SAMSUNG
23.2.2021 11:02:14 CET | Business Wire | Press release
Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today introduced Samsung ISOCELL GN2, a new 50-megapixel (Mp) image sensor with large 1.4-micrometer (μm)-sized pixels. With enhancements to its predecessor, the ISOCELL GN1, the GN2 offers up to 100Mp imaging, improved auto-focusing through Dual Pixel Pro technology, powerful staggered HDR, and vivid results through Smart ISO Pro, regardless of the lighting environment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210223005475/en/
“ISOCELL image sensors and its technologies have made vast improvements to deliver the quality and performance one would expect from top-tier prograde cameras,” said Duckhyun Chang, executive vice president of sensor business at Samsung Electronics. “Our new ISOCELL GN2 features Dual Pixel Pro, an innovative all-direction auto-focusing solution that elevates the agility to capture moments as they unfold. Adding on Smart ISO Pro and a variety of advanced pixel technologies, pictures from GN2 are more true-to-life than ever.”
The 1/1.12-inch ISOCELL GN2 is a highly versatile image sensor when it comes to image resolutions. With 50 million 1.4μm-sized pixels on hand, the GN2 offers exceptionally detailed photographs in regular settings. In low-lit environments such as indoors, the sensor can simulate a larger 2.8μm-pixel with four-pixel-binning technology to absorb more light, delivering brighter and sharper images.
For those who appreciate more detail in photographs or are prone to post-processing such as image cropping, the GN2 offers an option to take pictures in 100Mp resolutions. In 100Mp mode, the GN2 meticulously re-arranges the color pixels using an intelligent re-mosaic algorithm, creating three individual layers of 50Mp frames in green, red and blue. These frames are then up-scaled and merged to produce a single ultra-high 100Mp resolution photograph.
The ISOCELL GN2 is Samsung’s first image sensor to offer Dual Pixel Pro, the company’s most advanced phase-detection auto-focus solution yet. By employing two photodiodes within every pixel of the image sensor, Dual Pixel Pro makes use of one hundred million phase detecting agents for ultra-fast auto-focusing. In addition, the solution also offers all-direction focusing by splitting the pixels not only vertically, as with Dual Pixel, but also diagonally. This diagonal cut allows the focusing agents to better recognize the top and bottom of the frame, allowing the sensor to get in focus quickly even when there are no pattern changes in a horizontal direction. Low-light focusing and tracking of moving objects are improved as well, as every pixel of the sensor works as focusing agents.
For taking pictures in mixed-light environments, such as sunsets or indoors with daylight coming through a window, the GN2 increases its dynamic range with a staggered-HDR feature, a time-multiplexed HDR technology that uses rolling shutters over the same pixel arrays to capture multiple frames in short, middle, and long exposures. By maximizing the dynamic range, staggered-HDR ensures rich detail and vivid color in highlights and dark shadows within the scene, making it an ideal solution for shooting high-contrast sights. Staggered-HDR is able to reduce the energy consumption of a sensor by up to 24-percent when compared to the predecessor’s real-time HDR mode, contributing to improved energy efficiency of the overall system.
The GN2 also comes with Smart ISO and Smart ISO Pro. Smart ISO intelligently sets the sensor’s conversion gain, allowing the picture to be taken using an optimal ISO; low ISO for brighter outdoors or high for dimmer indoors. Unlike Smart ISO, which uses readouts from a single ISO per picture, Smart ISO Pro, which uses an intra-scene dual conversion gain (iDCG) solution, takes readouts from both high and low ISO to instantly create high dynamic range images with less motion-artifacts. In addition, in extreme low-light, Smart ISO Pro quickly takes and processes multiple frames in high ISO, raising the light sensitivity close to one-million ISOs and taking mobile night photography to greater heights.
Camera experiences can be more fun and creative with the GN2, where precious moments can be captured more dramatically and everyday events can be turned into short videos. The GN2 supports full-HD videos at 480 frames-per-second (fps) or 4K at 120fps, enabling wider possibilities for mobile video-shooting.
Samsung ISOCELL GN2 is currently in mass production.
About Samsung Electronics Co., Ltd.
Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at http://news.samsung.com .
# # #
* Samsung first announced its ISOCELL technology in 2013, which reduces color crosstalk between pixels by placing a physical barrier, allowing small-sized pixels to achieve higher color fidelity. Based on this technology, Samsung introduced the industry’s first 1.0μm-pixel image sensor in 2015 and a 0.9-pixel sensor in 2017. Samsung continues to enhance its pixel isolation methods with ISOCELL Plus and the ISOCELL 2.0 technologies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210223005475/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom